Context Therapeutics (CNTX) Shares Outstanding (2020 - 2026)

Context Therapeutics has disclosed Shares Outstanding across 7 years of filings, most recently posting $91.9 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $91.9 million, up 2.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $91.9 million (up 2.42% YoY), and the FY2025 annual result was $91.9 million, up 2.42% from the prior year.
• Shares Outstanding came in at $91.9 million for Q1 2026 at Context Therapeutics, roughly flat from $91.9 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $91.9 million in Q3 2025 to a low of $16.0 million in Q1 2022.
• The 5-year median for Shares Outstanding is $16.0 million (2022), against an average of $49.3 million.
• Peak annual rise in Shares Outstanding reached 4651.7% in 2022, while the deepest fall reached 0.0% in 2022.
• Context Therapeutics' Shares Outstanding stood at $16.0 million in 2022, then changed by 0.0% to $16.0 million in 2023, then jumped by 461.84% to $89.7 million in 2024, then rose by 2.42% to $91.9 million in 2025, then changed by 0.0% to $91.9 million in 2026.
• The last three Shares Outstanding figures came in at $91.9 million (Q1 2026), $91.9 million (Q4 2025), and $91.9 million (Q3 2025), per Business Quant data.